Calls
At ECRIN, we can provide support to investigators in preparing proposals for multinational clinical study funding, provided the project meets ECRIN’s eligibility criteria.
For more information on how ECRIN can support you in the preparation of these calls, see Clinical Trials Preparation and contact your local European Correspondent.
For more information and guidance on Horizon Europe funding schemes and opportunities, you are encouraged to contact your National Contact Point (NCP). Additional details on funding opportunities and events under Cluster 1 – Health are also available on the HNN3 network website, which brings together NCPs in the health area.
The calls listed below may be relevant for your applications for clinical trials / clinical research in various fields. In the News section of our website, you can also find additional information on calls on diverse topics other than clinical trials.
Discover the European funding programs for multinational clinical trials.
Call Launch :
Deadline :
Description :
The Paediatric clinical Research Infrastructure Service Model (PRISM) project aims to transform paediatric clinical research in Europe and Canada by creating a coordinated, transnational ecosystem of experienced infrastructures and service organisations. PRISM will deliver high-quality, innovative and sustainable clinical research support tailored for children and young people.
Funded under Horizon Europe (GA101292607), PRISM is a European consortium coordinated by ECRIN bringing together 23 key stakeholders from both Europe and Canada.
A first open call will be launched for Proposals on paediatric multinational investigator-initiated clinical studies funded. PRISM will select, according to a two-stage procedure, pilot paediatric clinical studies with the objective to provide a comprehensive, end-to-end support for multinational investigator-initiated studies conducted in 3 to 6 countries in Europe and Canada.
Here are the key deadlines:
- Mid-September 2026: official launch of the Call
- Mid-December 2026: deadline for Letters of Intent
Eligible projects include pragmatic comparative effectiveness trials, optimisation studies, repurposing trials or observational studies in any disease area except cancer and rare diseases.
Short-listed projects will get support from the PRISM consortium during the design and planning of the full application. Following final assessment, selected projects will receive funding covering the cost of investigation and trial coordination, and multinational trial management services provided by the PRISM consortium.
Links :
Call Launch :
Deadline :
Deadline 2 :
Description :
Innovative healthcare interventions for non-communicable diseases - Cluster 1 - Health (Two stage - 2027) (HORIZON-HLTH-2027-02-two-stage).
Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
- Researchers, developers and clinical practitioners have access to state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to develop innovative healthcare interventions aimed at reducing burden of the following specific Non-Communicable Diseases (NCDs): cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases.
- Scientific and clinical communities can use innovative healthcare interventions to generate meaningful advances in clinical practice and care for patients with NCDs following validation in late-stage clinical trials.
- Scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR[1] principles, thereby encouraging further use of the data.
- Policymakers, scientific and clinical communities, developers, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
- Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.
Call Launch :
Deadline :
Deadline 2 :
Description :
FORCE (Fostering Oncology Research by Charities in Europe) – Joint Call for Proposals 2027
“Quality of life–integrated approaches to improve treatment of rare and/or hard-to-treat cancers through pragmatic clinical trials”
The first FORCE call for projects aims to support international pragmatic clinical trials designed to optimize diagnostic and therapeutic strategies for patients with rare and/or hard-to-treat cancers, while strengthening the integration of robust, decision-relevant evidence generation across heterogeneous clinical settings. Particular emphasis is placed on the systematic incorporation of quality of life as a central component of trial evaluation.
Submission deadlines:
- Pre-proposals: 21 September 2026, 2pm CET
- Full proposals: Early 2027 Electronic proposal submission system: https://appelsaprojets.fondation-arc.org/
For further information, please visit the website or contact the Joint Call Secretariat at: Fondation ARC, France.
Links :
Call Launch :
Deadline :
Deadline 2 :
Description :
ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
ERDERA will open its Clinical Trial Call 2026 (ECTC) on 1 July 2026 to support multinational, GCP‑compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.
This call aims to generate robust clinical evidence and, where appropriate, data of regulatory relevance to support future regulatory interactions and subsequent clinical development. It is designed for rare disease trials where patient populations are often small and geographically dispersed, making multinational collaboration essential.
Priority areas (not eligibility criteria): paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.
Links :
Call Launch :
Deadline :
Deadline 2 :
Description :
Aging and Cancer 2026
The Samuel Waxman Institute for Aging & Cancer at the Mark Foundation for Cancer Research, in partnership with the American Cancer Society (ACS), Blood Cancer United, Blood Cancer UK, and Mike & Sofia Segal Foundation, is pleased to issue a request for proposals (RFP) to enable collaborations that bring together complementary expertise to address the fundamental role of aging in cancer. Applications addressing solid tumors and/or blood cancers are encouraged. Proposals must justify the partnership through synergistic scientific aims. Please see the Aging and Cancer RFP before applying.
Research supported by this program will advance our understanding of the rising incidence of cancer due to aging, with a special emphasis on the role of inflammaging and immunosenescence as common drivers of aging and cancer. Example topics include but are not limited to:
Identifying actionable biomarkers (inflammatory molecules, immune cells, etc.) that link aging and cancer risk, including in younger individuals with early onset cancers and those with genetic predispositions, and underlying mechanisms.
Dissecting the effects of the aging tumor microenvironment (e.g., inflammation, immune system, senescent cells) on tumorigenesis, progression, and treatment response.
Investigating how progression of age-related clonal hematopoiesis, myeloid skewing, or emergency myelopoiesis promotes hematological malignancies (including chronic myelomonocytic leukemia) or solid tumors, and/or causes therapeutic resistance.
Establishing the effects of tumors and cancer therapies in organismal aging, including the identification of biomarkers and therapeutic strategies to minimize or prevent cancer-induced aging.
Providing pre-clinical and mechanistic validation for aging-specific, anticancer therapeutic approaches based on strategies targeting inflammation or senescence, or nominated from clinical trial data segregated by age.
Supporting exploratory clinical trials to treat or prevent cancer in older or high-risk individuals, including correlative analyses from clinical samples derived from relevant trials. We encourage collaborations with biopharma or other funding sources to accelerate the proposed work.
Institutional Eligibility
Open to non-profit academic/research institutions worldwide.
The “host institution” is the institution of the Principal Investigator (PI) on the application.
Co-Principal Investigators (Co-PI) must be from a different institution.
The term “institution” will be interpreted broadly – for example, a medical school and academic department at the same university will be considered the same institution.
There is no requirement to include a US-based institution as part of the team.
Investigator Eligibility
There are no restrictions on citizenship or geography.
Applicants must have an independent faculty appointment (tenure-track or equivalent) at a non-profit academic/research institution.
Collaboration teams must consist of one principal investigator (PI) at the host institution and one co-principal investigator (co-PI) at a different institution. We encourage teams that bring together individuals with distinct expertise (e.g. a cancer investigator and computational expert, a cancer investigator and an aging expert who has not previously worked in the cancer field, or experts who study aging in oncology and immunology).
The PI and co-PI must both lead established laboratories currently supported by multi-year independent funding. For example, for US-based applicants, this should be at least one R01 or R01-equivalent grant. International applicants should similarly demonstrate independent support for their labs.
Investigators who currently hold “Aging and Cancer” awards from the Mark Foundation are not permitted to apply.
The PI and co-PI can only participate in one application, regardless of role.
Award Terms
The award will provide support of up to $500,000 to a team of two investigators for a term of three years, with $200,000 provided in Years 1 and 2 and $100,000 in Year 3. Ideally, the distribution should be even between the two investigators. The host institution will receive the grant funds.
Award recipients will be required to attend an annual scientific event sponsored by the Samuel Waxman Institute for Aging & Cancer.
Budget limits are inclusive of both direct and indirect costs, with indirect costs allowed up to 10% of the direct costs and included in the total grant amount.
Submission Process
Letters of Intent must be submitted through the online application system no later than 5 PM Eastern Time on June 15, 2026. Registration and email address verification are required. Notifications will be sent from the application system so please be sure these emails are not caught in spam filters.
Letters of Intent are limited to 1 page and should be formatted with 0.5-inch border and 10 font size. They must include:
- Proposal title
- Background
- Key preliminary data
- Premise and rigor of underlying research
- Hypothesis
- Specific aims
- Novelty
- Potential translational impact for aging and cancer
- Applicants will also be requested to provide a biosketch (NIH format or similar) that includes a list of current grants and other funding supporting the lab.
All application materials, including Letter of Intent and biosketch, must be submitted in English.
Invitations for full applications and funding decisions will be based on peer review by a committee of members of the Waxman Institute Scientific Advisory Board, Mark Foundation representatives, and the Scientific Review Committee.
Key Dates:
- Application portal opens: May 4, 2026
- Letters of intent due: June 15, 2026
- Notification of invitation to submit a full application: August 2026
- Full applications due: September 15, 2026
- Notification of award: October 2026
- Projects and funding start: January 1, 2027
Submit all inquiries to grants@themarkfoundation.org.
Call Launch :
Deadline :
Description :
IHI call 13
The following topics are under consideration for inclusion in IHI call 13, which IHI plans to launch in summer 2026.
- IHI European healthcare incubator network
- An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- Decode the immuno-science of age-related mediated diseases
The topics are currently under consultation with our States’ Representatives Group (SRG) and Science and Innovation Panel (SIP). They may therefore change considerably between the versions published here and the call launch, and applicants should check the final, approved topic texts once they are published.
Nevertheless, we strongly encourage anyone interested in these topics to start preparing a proposal and get networking with potential partners.
IHI will hold info sessions the call around the time of the call launch; these will cover the topics as well as our rules and procedures.
Information on eligibility for funding
Legal entities based in all countries associated to Horizon Europe, including Canada, Switzerland, the UK, and South Korea, will be eligible to receive funding under this call, in line with the normal rules.
Join us for the IHI Call Days
Information on the individual topics as well as rules and procedures for two-stage calls will be presented during four webinars from 24-30 June 2026. Find out more and register.
Links :
Call Launch :
Deadline :
Description :
Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) - Supporting the implementation of the Cancer Mission (HORIZON-MISS-2026-02-CANCER-05).
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes:
- Through the European Cancer Patient Digital Centre (ECPDC), adolescent and young cancer patients and survivors as well as their caregivers have access to innovative tools and approaches to strengthen their mental health.
- Healthcare professionals have access to innovative tools to monitor and support the mental health of cancer patients and survivors as well as their caregivers.
- Researchers and healthcare professionals have access and use reliable patient reported data to better understand the mental health needs of cancer patients and survivors and provide effective care.
Links :
Call Launch :
Deadline :
Description :
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers - Supporting the implementation of the Cancer Mission (HORIZON-MISS-2026-02-CANCER-03).
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:
- Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries;
- Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities;
- National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice.
Links :
Call Launch :
Deadline :
Description :
Virtual Human Twin (VHT) Models for Cancer Research - Supporting the implementation of the Cancer Mission (HORIZON-MISS-2026-02-CANCER-01).
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:
- Researchers of different disciplines use advanced multiscale Virtual Human Twins (VHTs) to expand the knowledge and understanding of cancer onset and progression
- Healthcare professionals and researchers have access to advanced VHT-based solutions that model cancer onset and progression over time, contributing to improve personalised treatments
- Researchers, healthcare professionals, innovators and citizens have access to cancer VHTs through the UNCAN.eu and the advanced Virtual Human Twin platforms
Links :